Last reviewed · How we verify
R-CHOP; R-DA-EPOCH; R-HD MTX
R-CHOP; R-DA-EPOCH; R-HD MTX is a Monoclonal antibody + chemotherapy combination Small molecule drug developed by Shandong Provincial Hospital. It is currently in Phase 3 development for B-cell non-Hodgkin lymphoma (various subtypes including diffuse large B-cell lymphoma), Primary CNS lymphoma (R-HD MTX regimen).
R-CHOP, R-DA-EPOCH, and R-HD MTX are combination chemotherapy regimens that use rituximab (an anti-CD20 monoclonal antibody) combined with various cytotoxic chemotherapy agents to target and destroy B-cell lymphomas.
R-CHOP, R-DA-EPOCH, and R-HD MTX are combination chemotherapy regimens that use rituximab (an anti-CD20 monoclonal antibody) combined with various cytotoxic chemotherapy agents to target and destroy B-cell lymphomas. Used for B-cell non-Hodgkin lymphoma (various subtypes including diffuse large B-cell lymphoma), Primary CNS lymphoma (R-HD MTX regimen).
At a glance
| Generic name | R-CHOP; R-DA-EPOCH; R-HD MTX |
|---|---|
| Sponsor | Shandong Provincial Hospital |
| Drug class | Monoclonal antibody + chemotherapy combination |
| Target | CD20 (rituximab component) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Rituximab binds to CD20 antigen on B-cell surfaces, triggering antibody-dependent cellular cytotoxicity and direct apoptosis. The chemotherapy components (cyclophosphamide, doxorubicin, vincristine, prednisone in CHOP; etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone in DA-EPOCH; high-dose methotrexate in R-HD MTX) work through DNA damage and cell cycle disruption. Together, these regimens provide synergistic anti-lymphoma activity.
Approved indications
- B-cell non-Hodgkin lymphoma (various subtypes including diffuse large B-cell lymphoma)
- Primary CNS lymphoma (R-HD MTX regimen)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea/vomiting
- Mucositis
- Infection
- Cardiotoxicity (doxorubicin-related)
- Infusion reactions (rituximab)
Key clinical trials
- Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma (PHASE3)
- Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma (PHASE3)
- R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- R-CHOP; R-DA-EPOCH; R-HD MTX CI brief — competitive landscape report
- R-CHOP; R-DA-EPOCH; R-HD MTX updates RSS · CI watch RSS
- Shandong Provincial Hospital portfolio CI
Frequently asked questions about R-CHOP; R-DA-EPOCH; R-HD MTX
What is R-CHOP; R-DA-EPOCH; R-HD MTX?
How does R-CHOP; R-DA-EPOCH; R-HD MTX work?
What is R-CHOP; R-DA-EPOCH; R-HD MTX used for?
Who makes R-CHOP; R-DA-EPOCH; R-HD MTX?
What drug class is R-CHOP; R-DA-EPOCH; R-HD MTX in?
What development phase is R-CHOP; R-DA-EPOCH; R-HD MTX in?
What are the side effects of R-CHOP; R-DA-EPOCH; R-HD MTX?
What does R-CHOP; R-DA-EPOCH; R-HD MTX target?
Related
- Drug class: All Monoclonal antibody + chemotherapy combination drugs
- Target: All drugs targeting CD20 (rituximab component)
- Manufacturer: Shandong Provincial Hospital — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for B-cell non-Hodgkin lymphoma (various subtypes including diffuse large B-cell lymphoma)
- Indication: Drugs for Primary CNS lymphoma (R-HD MTX regimen)
- Compare: R-CHOP; R-DA-EPOCH; R-HD MTX vs similar drugs
- Pricing: R-CHOP; R-DA-EPOCH; R-HD MTX cost, discount & access